Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpart

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst conse

BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest anal

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouragin

Wall Street analysts changed their outlook on top names. Check out the ratings page for complete cha

US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q

Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results

US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises th

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology plat

Company on track to report topline results early in the second quarter of 2026Second planned Data an

https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline result

Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, st

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers th

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst conse

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

  During Thursday's session, 406 companies made new 52-week lows.

  Monday saw 825 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday